J&J Rides Consumer Health ‘Growth Annuity’ As Rx, Device Divisions Slow

Johnson & Johnson’s second-quarter U.S. OTC sales jumped nearly 16% on the return of recalled brands and Worldwide Group Chairman Peterson says J&J expects the consumer business to grow “increasingly” more robust.